Emotional Awareness and Expression Therapy for Migraine
(EAET Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Utah

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial tests a new therapy called Emotional Awareness and Expression Therapy (EAET) for people with migraines. EAET helps individuals recognize and express difficult emotions to reduce stress and emotional pain. The goal is to see if this therapy can lower the frequency and severity of migraine attacks.

Eligibility Criteria

This trial is for adults aged 18-80 with a neurologist's diagnosis of episodic or chronic migraine. They must have had migraines for at least a year, experience them at least four days per month, and have been on stable medication for three months. People with serious psychiatric disorders, recent changes in migraine meds, or involvement in other treatment studies cannot join.

Inclusion Criteria

I have had migraines for at least a year.

I am between 18 and 80 years old.

I have been diagnosed with migraine by a neurologist.

+3 more

Exclusion Criteria

I haven't changed my migraine medication in the last 3 months.

Inability to use a computer and/or smartphone

Limited access to the internet

+10 more

Participant Groups

The study examines Emotional Awareness and Expression Therapy (EAET) to see if it can reduce the frequency and severity of migraines. Participants will be randomly placed into two groups: one receiving EAET through weekly online sessions and another as a control group that may receive treatment later.

2Treatment groups

Experimental Treatment

Active Control

Group I: Emotional Awareness and Expression Therapy (EAET)Experimental Treatment1 Intervention

In this experimental arm, participants are required to attend 8 online sessions and fill out questionnaires before treatment, and immediately after treatment.

Group II: Wait list controlActive Control1 Intervention

In this control arm, participants are required to wait 8 weeks until the treatment arm is completed and fill out questionnaires before and after the treatment date.